ArticleDiscover oncology2026
LncRNA regulation of pyroptosis determines prognostic outcomes and functional characteristics in liver cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyroptosis has been shown to play a dual role in the immune microenvironment and tumor progression of various cancers. Long noncoding RNAs (lncRNA) exert tumor suppressor or tumor promoter effects by regulating the expression of pyroptosis-related genes or the activity of signaling pathways. In this study, 30 differentially expressed genes related to pyroptosis were screened from 624 liver cancer patients’ RNA-seq datasets and 299 non-tumor adjacent tissue RNA-seq datasets, and 7 core genes were revealed to have significant co-expression relationships with multiple lncRNAs. Combined with lncRNA co-expression analysis and LASSO regression, three pyroptosis-related lncRNAs (pRLs) were finally identified (AC012615.1, AC099850.3 and AP001453.2) to construct a risk scoring model. Kaplan-Meier survival analysis showed that the overall survival time of patients in the low-risk group was significantly longer than that in the high-risk group (p < 0.001). ROC analysis showed that the model had a good predictive ability with a prediction AUC of 0.659, 0.657 and 0.751 for 1-year, 3-year and 5-year survival. Multivariate Cox regression confirmed that the risk score was an independent prognostic factor (HR > 1, p < 0.001). Functional enrichment analysis showed that patients in the high-risk group were enriched in proliferation pathways (cell cycle and nucleic acid metabolism), while those in the low-risk group were enriched in pathways related to immune regulation and metabolic balance. Tumor mutation burden (TMB) analysis found that the risk score was positively correlated with TMB level (r = 0.42, p < 0.0001), and patients in the high TMB + low-risk group had the best survival. Immune microenvironment analysis showed that the infiltration levels of CD4 + memory T cells, M0 macrophages, dendritic cells and neutrophils in the high-risk group were significantly increased (p < 0.05), and PD-L1 expression was upregulated. In vitro experiments found that lncRNA AC099850.3 was highly expressed in liver cancer, which could promote cell proliferation, migration, invasion and inhibit apoptosis (p < 0.05), participate in the malignant progression of liver cancer by regulating apoptosis genes, mutation-related genes and immune cell infiltration. This study revealed the clinical and biological significance of Pyroptosis-related lncRNA in liver cancer, and provided theoretical basis for early stratified diagnosis, individualized treatment and new target development of liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.